1. Home
  2. INFU vs GALT Comparison

INFU vs GALT Comparison

Compare INFU & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InfuSystems Holdings Inc.

INFU

InfuSystems Holdings Inc.

HOLD

Current Price

$9.60

Market Cap

182.4M

Sector

Health Care

ML Signal

HOLD

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

HOLD

Current Price

$2.81

Market Cap

199.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INFU
GALT
Founded
2005
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.4M
199.2M
IPO Year
2005
2008

Fundamental Metrics

Financial Performance
Metric
INFU
GALT
Price
$9.60
$2.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$15.00
$8.50
AVG Volume (30 Days)
112.2K
321.1K
Earning Date
05-07-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
181.82
N/A
EPS
0.31
N/A
Revenue
$143,436,000.00
N/A
Revenue This Year
$2.89
N/A
Revenue Next Year
$7.66
N/A
P/E Ratio
$30.97
N/A
Revenue Growth
6.36
N/A
52 Week Low
$4.61
$1.15
52 Week High
$11.04
$7.13

Technical Indicators

Market Signals
Indicator
INFU
GALT
Relative Strength Index (RSI) 62.04 42.95
Support Level $9.73 $2.57
Resistance Level $9.83 $3.37
Average True Range (ATR) 0.47 0.25
MACD 0.04 0.01
Stochastic Oscillator 93.89 5.47

Price Performance

Historical Comparison
INFU
GALT

About INFU InfuSystems Holdings Inc.

InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: